Today we are witnessing a systemic failure hidden in plain sight in a Global Market valued at over 14 Trillion Dollars today. Over 80% of dementia residents are prescribed more than 10 medications daily. Yet, despite being in an era of "precision medicine" most of these prescriptions are issued with total genetic blindness. At Link, our deep-dive into the intersection of technology and biology has revealed a sobering reality: We aren't just over-medicating our seniors, we are trapping them in a cycle of avoidable toxicity because our software systems, the "hospital clones" of yesterday and ignoring the patient's DNA.
Standard clinical practice is often a high-stakes game of "trial and error." A resident is agitated; they are prescribed an antipsychotic. They become lethargic and fall; they are prescribed something for the pain.
The missing link? Research shows that 30% to 90% of a person’s response to medication is dictated by their genes. Over 75% of the population has genetic variations in the CYP2D6 enzyme cluster—the very engine that processes nearly all dementia and psychotropic drugs.
When we prescribe without this data, we aren't "caring"—we are guessing. This "one-size-fits-all" approach leads to:
The Prescribing Cascade: Treating the side effect of one drug with another drug
The Fall Risk: Genetic "poor metabolizers" experience toxic buildup, leading to the dizziness and imbalances that cause catastrophic falls
Accelerated Decline: Inappropriate sedation masks the resident’s true cognitive state, stripping away their dignity and life story
At Link, we believe the Electronic Patient Record (EPR) must evolve or become obsolete. A record that only tells you "what happened" is a graveyard of data. A record that tells you "what will happen" is a tool for life.
Our careBridge platform is engineered to bridge this biological gap. By integrating Pharmacogenomics (PGx) directly into the eMAR (Electronic Medication Administration Record), we are creating the world’s first Biological Digital Twin .
How We Are Changing the Narrative:
DNA-Informed eMAR: Our system doesn't just record a dose; it flags if that dose is genetically incompatible with the resident’s metabolic profile before the pill is administered.
Ending the Trial-and-Error Cycle: We provide clinicians with a "DNA Medication Pass," reducing serious side effects by an average of 30% and significantly lowering the "chemical burden" on the resident.
The Humane AI Copilot: Our AI doesn't just look for patterns in notes; it looks for the delta between a resident's genetic potential and their current clinical state, flagging "micro-trends" of toxicity that human eyes might miss.
The "Fragmentation of Records" today are currently scrambling to meet the requirements of the EU AI Act. Link is already looking a decade ahead. We recognize that the future of health & social care isn't just "digital", it is personalized, sovereign and biological.
By solving the "Innovation Gap", we aren't just improving efficiency for providers or reducing burnout of family members & healthcare professionals. We are restoring the one thing that dementia so often steals that is "Dignity".
The question for the sector is no longer "Can we afford to innovate?" but "Can we afford to remain genetically blind?"